Children in Europe living with HIV are on course to receive a once-daily treatment after EU marketing authorisation (EMA) was given to ViiV Healthcare’s Triumeq PD.
The organization collaborates with companies across the pharma industry to create new, free resources to help improve diversity, equity, and inclusion in digitized clinical trials.
Recruiting and retaining patients on trials is one of the biggest hurdles the pharma industry faces, we spoke to Jonathan Eilberg to find out why and ways to tackle the ongoing issues.
Father and software engineer, Vincent Keunen combined his personal experience of leukemia and his son's bone cancer with his professional skills to provide all patients with a tool to manage their health information on their smartphone.
Guest article - Patient ID/recruitment and retention
Software that can enhance stroke patient outcomes by decreasing detection time and reducing disabilities is the first CE marked device that can help find large vessel occlusions (LVOs).
A survey conducted to understand whether supply issues over amoxicillin have persisted in the US found that an overwhelming majority of pharmacists are still struggling to source the commonly-used antibiotic.
The Dutch company Pharming Group N.V. has switched its rare disease drug leniolisib from an accelerated assessment to a regular review with the European Medicines Agency (EMA).
The US Food and Drug Administration (FDA) has accepted Merck’s Prevymis (letermovir) for prophylaxis of cytomegalovirus (CMV) disease in kidney transplant patients for priority review.
The clinical stage biopharmaceutical company will use its RADR artificial intelligence (AI) and machine learning platform to transform the cost, pace, and timeline of oncology drug discovery and development.
The partners announce that they will combine to use artificial intelligence to improve the identification and enrolment of patients for clinical trials.
The report compiles several of the key factors that are driving the growth of antimicrobial resistance, highlighting the pharmaceutical industry as a key economic sector driving the issue.
The company published a report finding that almost a fifth of trial sites only recruit one patient, Phesi’s CEO explained to Outsourcing-Pharma what the reaction at the event had been.
The two companies will come together to provide a ‘patient-centered solution’ for clinical research, combing uMotif’s patient engagement platform with ActiGraph’s wearable technology.
The company announces an addition to its portfolio of drug delivery devices, with its pen injector platform that is described as being more affordable to produce.
A study has shown that the use of exhaled volatile organic compounds (VOCs) can be used as biomarkers for differentially identifying liver disease on breath.
The pharma company provides funding to 24 community organizations throughout the US, as part of its newly created ‘Toward Health Equity Oncology Grant’.
One of the biggest questions being posed at this year's SCOPE summit, is whether the term 'decentralized clinical trials' will become redundant, as it forms the norm.
Here at OutsourcingPharma, we put our audience at the heart of what we do. For many years, we have provided our readers with a 360-degree view of the pharma landscape and our editorial standards remain unsurpassed.
Steve Rosenberg has been a life science and healthcare executive for 40+ years and is currently CEO of uMotif. He commercialized the first integrated clinical technology suite at Phase Forward/Oracle. Top pharma and biotech executives depend on him for...
Caroline Jackson is executive vice president for patient services at mdgroup and she will be delivering a presentation at SCOPE called 'Achieving the Impossible: Maximizing Patient Experience and Data Quality in a Complex Rare Disease Program.'...
The Summit for Clinical Ops Executives (SCOPE) is back with a four-day schedule that digs into strategies and technologies for tackling the perpetual problem of patient recruitment.
Amid incidents of toxic cough syrups, the organization has called on countries and regulators to strengthen action against the threat of substandard and falsified medical products.
Canadian CRO Nutrasource Pharmaceutical and Nutraceutical Services Inc has rebranded its clinical trial site as Apex Trials to expand its focus beyond food & natural health product trials.
Thread is one of a number of companies that are trying to address persistent problems with clinical trials such as recruitment and retention through DCT platforms that loosen, and for some programs sever, the link between geographic proximity to study...
Finch Therapeutics announced its shock decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) yesterday (Jan 25) saying instead it will focus on ‘realizing the value of its intellectual property estate and...
A partnership to put an end to the ‘tremendously manual and time-consuming’ collection of clinical data and medication history has been formed between health information (HIN) Health Gorilla and DrFirst, a healthcare technology solutions consultancy.
Hataali has introduced a new version of its blockchain-based advanced therapy platform to address one of the key supply chain challenges faced by contract manufacturers and pharma companies today.
